Status:
UNKNOWN
Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana
Lead Sponsor:
Navrongo Health Research Centre, Ghana
Collaborating Sponsors:
DBL -Institute for Health Research and Development
Conditions:
Malaria
Schistosomiasis
Eligibility:
All Genders
6-12 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if Artemisinin-based Combination Therapy, ACT,(artemether-lumefantrine) used as intermittent preventive treatment (IPT) alone or in combination with praziquan...
Detailed Description
Introduction: Malaria, schistosomiasis and soil-transmitted helminth (STH) infections are rife in sub-Saharan Africa where school children are at great risk of morbidity. Although the strategy of usin...
Eligibility Criteria
Inclusion
- Parental informed consent and assent by schoolchildren
- No known history of allergy to any study drug
- Aged 6 or more years
Exclusion
- lack of parental informed consent and assent by schoolchildren
- Known allergy or history of allergy to any study drug
- Aged less than 6 years
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2012
Estimated Enrollment :
345 Patients enrolled
Trial Details
Trial ID
NCT01459146
Start Date
December 1 2010
End Date
November 1 2012
Last Update
October 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHRC
Navrongo, Ghana